+++
title = "Quantumzyme Secures Patent for Enzymatic Ibuprofen Synthesis, Advancing Green Pharmaceutical Manufacturing"
date = "2025-09-24T12:11:15Z"
draft = false
summary = "Quantumzyme Corp. has achieved a significant milestone with the USPTO publication of its enzymatic ibuprofen synthesis patent, representing a major step toward sustainable pharmaceutical manufacturing that could transform industry practices."
description = "Quantumzyme patents enzymatic ibuprofen synthesis using modified polypeptides. This green chemistry breakthrough reduces environmental impact in pharmaceutical manufacturing through computational enzyme engineering."
source_link = "https://www.newmediawire.com/news/quantumzyme-corp-announces-uspto-publication-of-breakthrough-ibuprofen-patent-7082914"
enclosure = "https://cdn.newsramp.app/genai/images/259/24/0afe3b0c7b346afc6f6437f2cc154dd1.png"
article_id = 220415
feed_item_id = 21224
qrcode = "https://cdn.newsramp.app/newmediawire/qrcode/259/24/ulnaF7Bc.webp"
source = "NewMediaWire"
+++

<p>Quantumzyme Corp. has announced the official publication of its patent for enzymatic ibuprofen synthesis by the United States Patent and Trademark Office, marking a substantial advancement in green pharmaceutical manufacturing. The patent, titled "Modified Polypeptides for Enzymatic Synthesis of Ibuprofen" and published under number US20250146029A1, details a novel enzymatic process that offers a cleaner and more environmentally sustainable alternative to traditional chemical synthesis methods.</p><p>The company's innovative approach reduces reliance on harsh chemical reagents, minimizes reaction steps, and improves yield compared to conventional manufacturing processes. This technology positions Quantumzyme as a leader in developing future-ready solutions for Active Pharmaceutical Ingredient production through biocatalysis. According to CEO Naveen Kulkarni, the patent publication validates the company's scientific approach and commitment to sustainable innovation while opening opportunities for licensing and industry partnerships.</p><p>Quantumzyme's enzymatic process integrates quantum mechanics, molecular modeling, and AI-driven simulations to design high-performance biocatalysts. This methodology represents a significant shift toward more sustainable pharmaceutical manufacturing practices that could reduce environmental impact across the industry. The ibuprofen patent adds to the company's growing intellectual property portfolio and strengthens its position in enzyme-based solutions for pharmaceuticals, fragrances, food, and specialty chemicals.</p><p>The publication of this patent comes at a time when the pharmaceutical industry faces increasing pressure to adopt greener manufacturing practices. Quantumzyme's technology addresses this need by offering a scalable, cost-effective biocatalysis solution that could transform how common medications like ibuprofen are produced. For additional information, visit <a href="https://www.quantumzymecorp.com" rel="nofollow" target="_blank">https://www.quantumzymecorp.com</a> and <a href="https://www.otcmarkets.com/stock/QTZM" rel="nofollow" target="_blank">https://www.otcmarkets.com/stock/QTZM</a>.</p><p>This development represents Quantumzyme's ongoing commitment to revolutionizing chemical processes through sustainable, enzyme-based solutions. By combining computational modeling with wet-lab validation, the company aims to make eco-friendly biocatalysis the industry standard for pharmaceutical manufacturing, potentially addressing broader environmental challenges while maintaining production efficiency. The technology's implications extend beyond ibuprofen production, suggesting a pathway for transforming multiple pharmaceutical manufacturing processes toward greater sustainability and reduced environmental footprint.</p>